Aptevo Therapeutics Inc  

(Public, NASDAQ:APVO)   Watch this stock  
Find more results for APVO
-0.05 (-2.12%)
Oct 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.29 - 2.37
52 week 1.15 - 3.85
Open 2.34
Vol / Avg. 131,720.00/1.01M
Mkt cap 49.48M
P/E     -
Div/yield     -
EPS -5.29
Shares 21.42M
Beta     -
Inst. own 40%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -103.95% -308.54%
Operating margin -99.18% -348.42%
EBITD margin - -144.29%
Return on average assets -48.60% -102.37%
Return on average equity -79.50% -161.53%
Employees 118 -
CDP Score - -


2401 4th Ave Ste 1050
SEATTLE, WA 98121-3460
United States - Map
+1-206-8380500 (Phone)
+1-302-6555049 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).